|
1
|
Prince ME, Sivanandan R, Kaczorowski A,
Wolf GT, Kaplan MJ, Dalerba P, Weissman IL, Clarke MF and Ailles
LE: Identification of a subpopulation of cells with cancer stem
cell properties in head and neck squamous cell carcinoma. Proc Natl
Acad Sci USA. 104:pp. 973–978. 2007; View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Visvader JE and Lindeman GJ: Cancer stem
cells in solid tumours: Accumulating evidence and unresolved
questions. Nat Rev Cancer. 8:755–768. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Rich JN: Cancer stem cells in radiation
resistance. Cancer Res. 67:8980–8984. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Khan IN, Al-Karim S, Bora RS, Chaudhary AG
and Saini KS: Cancer stem cells: A challenging paradigm for
designing targeted drug therapies. Drug Discov Today. 20:1205–1216.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Gupta GP and Massagué J: Cancer
metastasis: Building a framework. Cell. 127:679–695. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Thiery JP and Sleeman JP: Complex networks
orchestrate epithelial-mesenchymal transitions. Nat Rev Mol Cell
Biol. 7:131–142. 2006. View
Article : Google Scholar : PubMed/NCBI
|
|
7
|
Thiery JP, Acloque H, Huang RY and Nieto
MA: Epithelial-mesenchymal transitions in development and disease.
Cell. 139:871–890. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Sampieri K and Fodde R: Cancer stem cells
and metastasis. Semin Cancer Biol. 22:187–193. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Scheel C and Weinberg RA: Cancer stem
cells and epithelial-mesenchymal transition: Concepts and molecular
links. Semin Cancer Biol. 22:396–403. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Barbazán J, Muinelo-Romay L, Vieito M,
Candamio S, Díaz-López A, Cano A, Gómez-Tato A, Casares de Cal Mde
L, Abal M and López-López R: A multimarker panel for circulating
tumor cells detection predicts patient outcome and therapy response
in metastatic colorectal cancer. Int J Cancer. 135:2633–2643. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Warnakulasuriya S: Global epidemiology of
oral and oropharyngeal cancer. Oral Oncol. 45:309–316. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Huang SH and O'Sullivan B: Oral cancer:
Current role of radiotherapy and chemotherapy. Med Oral Patol Oral
Cir Bucal. 18:e233–e240. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Chang JT, Chen IH, Liao CT, Wang HM, Hsu
YM, Hung KF, Lin CJ, Hsieh LL and Cheng AJ: A reverse transcription
comparative real-time PCR method for quantitative detection of
angiogenic growth factors in head and neck cancer patients. Clin
Biochem. 35:591–596. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Chen YJ, Chang JT, Liao CT, Wang HM, Yen
TC, Chiu CC, Lu YC, Li HF and Cheng AJ: Head and neck cancer in the
betel quid chewing area: Recent advances in molecular
carcinogenesis. Cancer Sci. 99:1507–1514. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Liao CT, Chang JT, Wang HM, Ng SH, Hsueh
C, Lee LY, Lin CH, Chen IH, Huang SF, Cheng AJ and Yen TC: Analysis
of risk factors of predictive local tumor control in oral cavity
cancer. Ann Surg Oncol. 15:915–922. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Lee W, Yoo H, Kim JA, Lee S, Jee JG, Lee
MY, Lee YM and Bae JS: Barrier protective effects of
piperlonguminine in LPS-induced inflammation in vitro and in vivo.
Food Chem Toxicol. 58:149–157. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Yao L, Chen HP and Ma Q: Piperlongumine
alleviates lupus nephritis in MRL-Fas(lpr) mice by regulating the
frequency of Th17 and regulatory T cells. Immunol Lett. 161:76–80.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Son DJ, Kim SY, Han SS, Kim CW, Kumar S,
Park BS, Lee SE, Yun YP, Jo H and Park YH: Piperlongumine inhibits
atherosclerotic plaque formation and vascular smooth muscle cell
proliferation by suppressing PDGF receptor signaling. Biochem
Biophys Res Commun. 427:349–354. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Raj L, Ide T, Gurkar AU, Foley M, Schenone
M, Li X, Tolliday NJ, Golub TR, Carr SA, Shamji AF, et al:
Selective killing of cancer cells by a small molecule targeting the
stress response to ROS. Nature. 475:231–234. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Bezerra DP, Pessoa C, de Moraes MO,
Saker-Neto N, Silveira ER and Costa-Lotufo LV: Overview of the
therapeutic potential of piplartine (piperlongumine). Eur J Pharm
Sci. 48:453–463. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Randhawa H, Kibble K, Zeng H, Moyer MP and
Reindl KM: Activation of ERK signaling and induction of colon
cancer cell death by piperlongumine. Toxicol In Vitro.
27:1626–1633. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Bharadwaj U, Eckols TK, Kolosov M,
Kasembeli MM, Adam A, Torres D, Zhang X, Dobrolecki LE, Wei W,
Lewis MT, et al: Drug-repositioning screening identified
piperlongumine as a direct STAT3 inhibitor with potent activity
against breast cancer. Oncogene. 34:1341–1353. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Jin HO, Lee YH, Park JA, Lee HN, Kim JH,
Kim JY, Kim B, Hong SE, Kim HA, Kim EK, et al: Piperlongumine
induces cell death through ROS-mediated CHOP activation and
potentiates TRAIL-induced cell death in breast cancer cells. J
Cancer Res Clin Oncol. 140:2039–2046. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Roh JL, Kim EH, Park JY, Kim JW, Kwon M
and Lee BH: Piperlongumine selectively kills cancer cells and
increases cisplatin antitumor activity in head and neck cancer.
Oncotarget. 5:9227–9238. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Shrivastava S, Kulkarni P, Thummuri D,
Jeengar MK, Naidu VG, Alvala M, Redddy GB and Ramakrishna S:
Piperlongumine, an alkaloid causes inhibition of PI3K/Akt/mTOR
signaling axis to induce caspase-dependent apoptosis in human
triple-negative breast cancer cells. Apoptosis. 19:1148–1164. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Wang XQ, Wang YC, Guo YT and Tang X:
Effect of piperlongumine on drug resistance reversal in human
retinoblastoma HXO-RB44/VCR and SO-Rb50/CBP cell lines. Int J Clin
Exp Pathol. 8:2525–2534. 2015.PubMed/NCBI
|
|
27
|
Bleau AM, Hambardzumyan D, Ozawa T,
Fomchenko EI, Huse JT, Brennan CW and Holland EC: PTEN/PI3K/Akt
pathway regulates the side population phenotype and ABCG2 activity
in glioma tumor stem-like cells. Cell Stem Cell. 4:226–235. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Shostak K and Chariot A: NF-κB, stem cells
and breast cancer: The links get stronger. Breast Cancer Res.
13:2142011. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Matsuda K, Sato A, Okada M, Shibuya K,
Seino S, Suzuki K, Watanabe E, Narita Y, Shibui S, Kayama T and
Kitanaka C: Targeting JNK for therapeutic depletion of stem-like
glioblastoma cells. Sci Rep. 2:5162012. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Lu YC, Chen YJ, Wang HM, Tsai CY, Chen WH,
Huang YC, Fan KH, Tsai CN, Huang SF, Kang CJ, et al: Oncogenic
function and early detection potential of miRNA-10b in oral cancer
as identified by microRNA profiling. Cancer Prev Res (Phila).
5:665–674. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Chen CY, Lin YS, Chen CL, Chao PZ, Chiou
JF, Kuo CC, Lee FP, Lin YF, Sung YH, Lin YT, et al: Targeting
annexin A2 reduces tumorigenesis and therapeutic resistance of
nasopharyngeal carcinoma. Oncotarget. 29:26946–26959. 2015.
View Article : Google Scholar
|
|
32
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Chen YJ, Lee LY, Chao YK, Chang JT, Lu YC,
Li HF, Chiu CC, Li YC, Li YL, Chiou JF and Cheng AJ: DSG3
facilitates cancer cell growth and invasion through the
DSG3-plakoglobin-TCF/LEF-Myc/cyclin D1/MMP signaling pathway. PLoS
One. 8:e640882013. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Guo Y, Liu S, Wang P, Zhao S, Wang F, Bing
L, Zhang Y, Ling EA, Gao J and Hao A: Expression profile of
embryonic stem cell-associated genes Oct4, Sox2 and Nanog in human
gliomas. Histopathology. 59:763–775. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Chiu CC, Lee LY, Li YC, Chen YJ, Lu YC, Li
YL, Wang HM, Chang JT and Cheng AJ: Grp78 as a therapeutic target
for refractory head-neck cancer with CD24(−)CD44(+) stemness
phenotype. Cancer Gene Ther. 20:606–615. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Brabletz T: EMT and MET in metastasis:
Where are the cancer stem cells? Cancer Cell. 22:699–701. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Clarke MF, Dick JE, Dirks PB, Eaves CJ,
Jamieson CH, Jones DL, Visvader J, Weissman IL and Wahl GM: Cancer
stem cells-perspectives on current status and future directions:
AACR Workshop on cancer stem cells. Cancer Res. 66:9339–9344. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Boyer LA, Lee TI, Cole MF, Johnstone SE,
Levine SS, Zucker JP, Guenther MG, Kumar RM, Murray HL, Jenner RG,
et al: Core transcriptional regulatory circuitry in human embryonic
stem cells. Cell. 122:947–956. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Loh YH, Wu Q, Chew JL, Vega VB, Zhang W,
Chen X, Bourque G, George J, Leong B, Liu J, et al: The Oct4 and
Nanog transcription network regulates pluripotency in mouse
embryonic stem cells. Nat Genet. 38:431–440. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Tsai LL, Yu CC, Chang YC, Yu CH and Chou
MY: Markedly increased Oct4 and Nanog expression correlates with
cisplatin resistance in oral squamous cell carcinoma. J Oral Pathol
Med. 40:621–628. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Ling GQ, Chen DB, Wang BQ and Zhang LS:
Expression of the pluripotency markers Oct3/4, Nanog and Sox2 in
human breast cancer cell lines. Oncol Lett. 4:1264–1268.
2012.PubMed/NCBI
|
|
42
|
Niwa H, Burdon T, Chambers I and Smith A:
Self-renewal of pluripotent embryonic stem cells is mediated via
activation of STAT3. Genes Dev. 12:2048–2060. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Do DV, Ueda J, Messerschmidt DM,
Lorthongpanich C, Zhou Y, Feng B, Guo G, Lin PJ, Hossain MZ, Zhang
W, et al: A genetic and developmental pathway from STAT3 to the
OCT4-NANOG circuit is essential for maintenance of ICM lineages in
vivo. Genes Dev. 27:1378–1390. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Siu A, Lee C, Dang D and Ramos DM: Stem
cell markers as predictors of oral cancer invasion. Anticancer Res.
32:1163–1166. 2012.PubMed/NCBI
|
|
45
|
Yin X, Zhang BH, Zheng SS, Gao DM, Qiu SJ,
Wu WZ and Ren ZG: Coexpression of gene Oct4 and Nanog initiates
stem cell characteristics in hepatocellular carcinoma and promotes
epithelial-mesenchymal transition through activation of Stat3/Snail
signaling. J Hematol Oncol. 8:232015. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Fan F, Samuel S, Evans KW, Lu J, Xia L,
Zhou Y, Sceusi E, Tozzi F, Ye XC, Mani SA and Ellis LM:
Overexpression of snail induces epithelial-mesenchymal transition
and a cancer stem cell-like phenotype in human colorectal cancer
cells. Cancer Med. 1:5–16. 2012. View
Article : Google Scholar : PubMed/NCBI
|
|
47
|
Guo W, Keckesova Z, Donaher JL, Shibue T,
Tischler V, Reinhardt F, Itzkovitz S, Noske A, Zürrer-Härdi U, Bell
G, et al: Slug and Sox9 cooperatively determine the mammary stem
cell state. Cell. 148:1015–1028. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Yasui K, Shimamura M, Mitsutake N and
Nagayama Y: SNAIL induces epithelial-to-mesenchymal transition and
cancer stem cell-like properties in aldehyde
dehydroghenase-negative thyroid cancer cells. Thyroid. 23:989–996.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Masui T, Ota I, Yook JI, Mikami S, Yane K,
Yamanaka T and Hosoi H: Snail-induced epithelial-mesenchymal
transition promotes cancer stem cell-like phenotype in head and
neck cancer cells. Int J Oncol. 44:693–699. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Diehn M, Cho RW, Lobo NA, Kalisky T, Dorie
MJ, Kulp AN, Qian D, Lam JS, Ailles LE, Wong M, et al: Association
of reactive oxygen species levels and radioresistance in cancer
stem cells. Nature. 458:780–783. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Yao JX, Yao ZF, Li ZF and Liu YB:
Radio-sensitization by Piper longumine of human breast adenoma
MDA-MB-231 cells in vitro. Asian Pac J Cancer Prev. 15:3211–3217.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Han JG, Gupta SC, Prasad S and Aggarwal
BB: Piperlongumine chemosensitizes tumor cells through interaction
with cysteine 179 of IkappaBalpha kinase, leading to suppression of
NF-κB-regulated gene products. Mol Cancer Ther. 13:2422–2435. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Kang Q and Yan S: Piperlongumine reverses
doxorubicin resistance through the PI3K/Akt signaling pathway in
K562/A02 human leukemia cells. Exp Ther Med. 9:1345–1350. 2015.
View Article : Google Scholar : PubMed/NCBI
|
